In the UK, access to anti-TNF therapies for the treatment of rheumatoid arthritis (RA) is standardized by National Institute for Clinical Excellence guidance. Certolizumab pegol (CZP) studies in RA demonstrate that patient response to therapy at 12 weeks predicts clinical outcome at 1 year. In the UK, CZP is available via a Patient Access Scheme (PAS), providing CZP free for the first 12 weeks. This analysis examines persistency and potential cost savings realised with a 12 week CZP decision. METHODS: A retrospective analysis examined 2,744 patients receiving CZP between March 2010 and March 2012 from Healthcare at Home, a UK home health care service provider. Persistence was defined as patients (%) continuing to receive CZP deliveries, calculated at specific time points. Treatment start was first delivery date and patients were censored according to this. A simple cost analysis was performed. RESULTS: At 13, 26, 39 and 52 weeks, persistence rates were 93%, 79%, 70% and 65% in naive (no prior anti-TNF) and 88%, 68%, 56% and 48% in switch (Ն1 prior anti-TNF) patients respectively. Analyzing first-line biologic drug costs only, the NHS would save £2,363.14/patient in the first year if CZP were used instead of adalimumab (assuming similar persistence); largely due to the PAS. Stopping treatment for non-responders at Week 12 (CZP) vs Week 24 (adalimumab), could allow the UK NHS to re-invest £ 2145/patient. CONCLUSIONS: In this UK cohort, CZP persistence was higher in naive pts. Reinforcing a 12 week treatment decision could result in more efficient spend on drugs and rapid initiation of alternative treatment in non-responders. 
MA3 PALIPERIDONE PALMITATE LONG-ACTING INJECTION FOR BRAZILIAN NON-ADHERENT SCHIZOPHRENIC PATIENTS: 5-YEAR BUDGET IMPACT ANALYSIS FROM THE PUBLIC PAYER PERSPECTIVE

OBJECTIVES:
To estimate the budget impact of PP-LAI in treating chronic schizophrenia in Brazil from the perspective of the public payer, specifically for patients with adherence issues. METHODS: The budget impact model (BIM) was used to estimate eligible population and to project investments for the first 5y (2012) (2013) (2014) (2015) (2016) ). An approach based on prevalence and adherence rates reported by previous studies was employed to define the eligible population. Two scenarios were simulated: 1) the current setting, in which schizophrenic patients with adherence issues receive atypical drugs already provided by the Brazilian Public Healthcare System (BPHS) (olanzapine, quetiapine and ziprasidone), and 2) the proposed setting, in which patients presenting non-adherence behaviors on oral atypical therapy can receive PP-LAI. Final costs were calculated considering drug acquisition costs and health resource consumption related to outpatient follow-up, hospitalizations and adverse events. RESULTS: The BIM estimated the population eligible for PP-LAI ranging from 2,207 patients (2012) to 2,271 patients (2016), approximately 0.3% of the projected schizophrenia population attending BPHS services. With all drugs tax exempted, the acquisition costs were: PP-LAI 5,566BRL (1st year) and 4,963BRL (subsequent years); olanzapine 3,850BRL; quetiapine 5,416BRL; ziprasidone 1,474BRL. The model estimated the current BPHS expenses at 287 million BRL in 2012, reaching 296 million BRL in 2016. If PP-LAI is included in the reimbursement list, the yearly budget impact in 2012 would be 2.4 million (ϩ0.83%) and 1.1 million in 2016 (ϩ0.37%). The cumulative budget impact would reach 6,658,573BRL in 5 years. CONCLUSIONS: PP-LAI is an effective therapeutic option for schizophrenic patients, particularly those who would benefit from LAI antipsychotic drugs. In this BIM, the investments to include PP-LAI on BPHS reimbursement lists were estimated to be BRL 6.7 million in five years (an increment of 0.46% in the current budget). 
MA4 ADEQUATE ADHERENCE TO INTRANASAL CORTICOSTEROIDS IS ASSOCIATED WITH SIGNIFICANTLY REDUCED NUMBER AND COSTS OF OUTPATIENT VISITS AMONG PATIENTS NEWLY DIAGNOSED WITH ALLERGIC RHINITIS
OBJECTIVES:
To develop a comprehensive model to estimate health and cost outcomes associated with different therapeutic options in major depressive disorder (MDD), accounting for long-term clinical events and treatment pathways. METHODS: A discrete event simulation (DES) model was developed with a flexible time horizon. This model simulated short-and long-term clinical events (partial response, remission, relapse, recovery, recurrence), adverse events, and treatment changes (titration, switch, addition, discontinuation) in a cohort of MDD patients. Patient characteristics influencing clinical evolution were considered (e.g., residual symptoms). The model was tested using fictitious antidepressants with three levels of efficacy, tolerability and drug cost (low, medium, high) from first-line to third-line. In the base case analysis, a medium-profile antidepressant was used first-line, and profiles of subsequent treatment lines depended on reason for switch (lack of efficacy or low tolerability). Input data were derived from the literature. Model outputs included time by clinical state, QALYs and costs. Costs were estimated for the UK, from payer and societal perspectives. One-way sensitivity analyses were performed. This model will be provided open source so that all interested researchers can contribute by incorporating new features or adding input data. RESULTS: Predicted costs and QALYs from this model are within the range of results from previous economic evaluations. The largest cost components from payer perspective were physician visits and hospitalisations. Key parameters driving the predicted costs and QALYs were utility values, effectiveness and frequency of physician visits. Differences in QALYs and costs between two strategies with different effectiveness increased approximately two-fold when the time horizon increased from 1 to 5 years. CONCLUSIONS: This DES model can provide a more comprehensive evaluation of different therapeutic options in MDD, compared to existing Markov models and can be used to compare a wide range of health care technologies in various groups of MDD patients. 
MO2 IMPACT OF STRUCTURAL ASSUMPTIONS ON COST-EFFECTIVENESS OUTCOMES: TOWARDS A STANDARDIZED COST-EFFECTIVENESS MODEL FOR ADJUVANT BREAST CANCER THERAPIES
OBJECTIVES:
Markov models developed for cost-effectiveness analysis (CEAs) often contain differences in model structure due to differences in assumptions. Such differences may lead to differences in outcome and can therefore impact decision making. The objective of this analysis was to identify structural assumptions, reported for CEAs comparing the cost-effectiveness of tamoxifen and anastrazole for adjuvant breast cancer therapy, and to subsequently evaluate the impact of these assumptions, both individually as well as combined, on analysis outcome measures. METHODS: Based on a literature review of available published Markov model based CEAs comparing tamoxifen and anastrazole, structural model assumptions were identified. Subsequently, a base case model was defined and built in R, representing the fundamental structure present in all identified CEAs from literature. Subsequently, different structural model components as identified from the published CEAs, were added to the base case model separately, as well as simultaneously. Outcome measures Life Years gained (LYG) and incremental costs were calculated for each of these models. The 21-gene assay was evaluated by simulating a hypothetical cohort of 50-year old women over a lifetime time horizon using a discrete event simulation. Main model outcomes were life-years gained, quality-adjusted life-years (QALYs) and costs. Based on the new ISPOR-SMDM best practice recommendations, the model has been validated. Major focus was on our experiences of the cross validation, i.e. the comparison of modeling results between the discrete-eventsimulation ONCOTYROL-model and the THETA-model (Toronto Health Economics and Technology Assessment Collaborative) which is a Markov model. Therefore, the Oncotyrol-model has been populated with the Canadian THETAmodel parameters. Cross validation started with a comparison of the natural history followed by QALYs and costs. RESULTS: The relative differences varied among the model outcomes. The smallest differences we found for costs, the highest for QALYs. All differences were smaller than 2.5%. The comparison of the efficiency frontiers showed that small differences due to the modeling approach can lead to a different set of non-dominated test-treatment strategies. The cross model validation involved several challenges: distinguishing between outcomes differences due to different modeling techniques and errors, definitions for meaningful differences and comparison techniques (mean estimates, distributions, multivariate outcomes). CONCLUSIONS: Cross-model validation was crucial to identify and correct modeling errors and to explain remaining differences of modeling results. However, small differences can lead to relevant changes in cost-effectiveness results. 
MO3 LESSONS LEARNED FROM A CROSS-VALIDATION BETWEEN A DISCRETE-EVENT SIMULATION MODEL AND A MARKOV MODEL FOR PERSONALIZED BREAST CANCER TREATMENT
MO4 TREATMENT DISCONTINUATION IN ECONOMIC MODELLING OF ONCOLOGY THERAPIES: SYSTEMATIC REVIEW AND BEST PRACTICES ANALYSIS
OBJECTIVES:
Compliance and treatment duration can have a significant impact on costs and health outcomes in health-economic assessments, especially in high-cost therapy areas such as oncology. The objective of this study was to systematically review different methods for addressing treatment compliance and discontinuation in oncology economic models, critique the identified methodologies, and highlight best practices. METHODS: A systematic review was undertaken to investigate the different methods that could be used to include compliance and treatment discontinuation in economic modelling in oncology populations. MEDLINE, Embase, EconLit and the Cochrane Library (from 2000 onwards), and technology assessment documents and manufacturer submissions to the National Institute for Health and Clinical Excellence (NICE) were searched for economic analyses which mentioned compliance or discontinuation. Results were filtered using pre-specified selection criteria and data extracted into a pre-defined template. RESULTS: Sixty-eight publications of 51 models were included, comprising 20 journal publications and 48 technology appraisal documents. Possible methods were divided into ten categories. Seven studies mentioned discontinuations, but did not include a modelling approach. There was a lack of consensus regarding the methods applied. Twenty studies varied dose or discontinuation rate in sensitivity analyses, although impact on overall outcomes was rarely explored. Dose intensity was most often adopted from clinical trials. Effects on the overall outcomes by inclusion of discontinuations or dose intensity adjustments were rarely discussed. Overall, the authors of included publications poorly justified their methods regarding compliance assumptions. CONCLUSIONS: The combination of several methods could improve accuracy of modelling discontinuations. Discontinuations should affect three aspects of the model: transition probabilities, costs and effects. Clear explanations and justification of the included parameter assumptions should also be improved in NICE submissions to enhance likelihood of positive recommendation. Standardised guidelines could raise more attention to compliance in economic modelling and could improve the accuracy of economic models.
PODIUM SESSION II: PATIENT HEALTH CARE ACCESS
PA1 ASSESSING THE PROGRESSION OF THE UK NHS HEALTH CARE REFORMS AND THE IMPACT ON HEALTH CARE DELIVERY
McConkey D, White R Double Helix Consulting, London, UK OBJECTIVES: The UK NHS is currently undergoing the most significant reforms to its structure possibly since the NHS was formed. There are many questions at all levels regarding the reforms, and this research aimed to address some of them The objectives were -1) To assess how the reforms were proceeding and what issues they had been encountered, and 2) To determine how the delivery of care has been impacted at a grassroots level. METHODS: We adopted a two phased approach. The first phase involved extensive literature review in order to assess how the reforms were expected to proceed, what the outcomes were likely/expected to be and when key milestones were expected to be met. The second phase was centred on primary research carried out by Double Helix personnel. Key stakeholders in the reforming NHS at all levels were approached and data was collected using a combination of qualitative and quantitative methodologies. RESULTS: While the vision of the NHS reforms was very clear from the outset, the actual progression on the ground has been met with considerable challenges. Even while CCGs in the first wave were in the process of undergoing assessment, changes to the overall architecture of the reforms were continuous. Key personnel at all levels lacked a clear grasp of what the following 12 months would bring, and various influencer and guideline bodies faced uncertain futures or lacked a clear remit. At the stage of writing there was no clear evidence either way to suggest that the reforms were having an impact on frontline health care delivery. CONCLUSIONS: The UK NHS Reforms were always going to be challenging due to their scale and complexity. However there has been a clear lack of direction at various levels leading to uncertainty and fears for the short and medium term future.
